Bharat Parenterals Peer Comparison

BSE: 541096

₹1,550.00

₹8.30 (0.54%)

As on 22-Sep-2026 11:05IST

Market cap

₹1,075 Cr

Revenue (TTM)

₹323 Cr

P/E Ratio

P/B Ratio

3.4

Div. Yield

0.1 %

Edit

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	1,075	21,460	20,797	17,919	18,493
Revenue (₹ Cr)	323	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	-29.99	678.07	273.51	666.92	735.15
Net Margin (%)	-9.01	28.10	16.19	20.60	26.88
RoE (%)	-4.72	19.73	11.15	18.75	19.16
Price to Earnings	--	32.25	69.95	27.83	25.16
Price-To-Book	3.37	5.84	7.74	4.44	4.20

Income Statement (₹ Cr)

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	323.17	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	332.76	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	312.59	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	10.58	796.58	478.55	1,139.61	941.63
Depreciation	34.33	78.10	126.01	281.06	57.58
EBIT	-23.75	718.48	352.55	858.55	884.05
Interest	11.31	0.88	52.11	190.64	7.69
Other Income	9.60	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	-25.46	843.56	319.96	658.12	992.82
Provision for Tax	4.53	165.49	46.45	-8.80	257.67
Profit after Tax	-29.99	678.07	273.51	666.92	735.15

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	322.23	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	14.59	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	144.32	28.74	266.35	1,392.75	91.50
Current Liabilities	157.39	385.94	848.06	2,077.10	627.48
Total Liabilities	620.18	4,037.51	3,705.61	7,246.72	4,921.88

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	293.10	1,291.22	2,525.44	5,617.77	770.28
Current Assets	310.08	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	620.18	4,037.51	3,705.61	7,246.72	4,921.88
Total Debt*	146.11	0.57	657.97	2,309.68	2.50
Net Current Assets	152.69	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	21.52	17.53	160.01	51.57	370.49

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	38.36	523.24	342.18	537.99	967.57
Cash Flow from Investing Activities	9.32	-582.30	-325.92	-369.46	-561.67
Cash from Financing Activities	-47.05	-46.46	13.62	-313.53	-798.31
Net Cash Inflow / Outflow	0.64	-105.52	29.88	-145.00	-392.41

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	-1.82	24.97	11.43	14.47	23.39
ROE (%)	-4.72	19.73	11.15	18.75	19.16
ROA (%)	-4.75	18.69	7.80	9.26	14.95
EBIT Margin (%)	-7.35	31.41	20.95	26.58	34.40
Net Margin (%)	-9.01	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	-11.19	15.01	27.91	9.59	10.69
EBIT Growth (%)	-3.75	18.45	58.32	16.84	24.14
Net Profit Growth (%)	15.99	19.61	149.56	62.68	-9.09
EPS Growth (%)	-152.62	17.73	-3.57	67.41	14.40
Book Value Growth (%)	-2.55	26.75	9.67	36.71	-0.34

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	-69.12	31.50	74.73	27.20	23.95
Price / Book Value	3.34	5.71	7.80	4.45	4.19
Dividend Yield (%)	0.06	0.29	0.06	0.00	1.86
EV/EBITDA	112.82	25.04	45.05	17.72	16.32
Market Cap (₹ Cr)	620.46	11,439.22	6,819.66	17,980.08	21,592.90

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.38	0.00	0.07	0.24	0.00
Short term debt to equity ratio	0.05	0.00	0.16	0.12	0.00
Current Ratio	1.97	6.70	1.31	0.74	6.06
Quick Ratio	1.43	5.59	0.88	0.53	5.31
Interest Coverage	-1.25	959.59	7.14	4.45	130.11

	Bharat Parenterals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	46.62	36.10	30.84	21.07	7.07
Asset Turnover	0.51	0.63	0.48	0.45	0.52
Receivable days	170.08	121.68	113.81	63.88	26.06
Inventory Days	82.65	63.83	84.76	43.27	65.95
Payable days	131.69	108.28	101.94	151.85	81.01
Cash Conversion Cycle	121.04	77.23	96.62	-44.70	11.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.